Bouhairie Malek Michael, Elseblani Racha, Lakis Remi, Hallal Mahmoud
Department of Gastroenterology and Hepatology, Faculty of Medicine, Lebanese University, Beirut, LBN.
Department of Reanimation and Anesthesiology, Faculty of Medicine, Lebanese University, Beirut, LBN.
Cureus. 2024 Jun 14;16(6):e62365. doi: 10.7759/cureus.62365. eCollection 2024 Jun.
Aim Estimate the prevalence of gastric polyps linked to long-term use of proton pump inhibitor (PPI), determine the various risk factors that promote this association, and identify the characteristics associated with these polyps. Methods This prospective cross-sectional study was conducted on approximately 1000 patients presenting to the Gastroenterology Endoscopic Department for upper GI endoscopy at two hospital centers in Beirut, Lebanon, over a period of 12 months from September 2021 to September 2022. The demographic and clinical data of patients who had been taking PPIs for at least one month were collected via a questionnaire. All patients with a previous Helicobacter pylori (H. pylori) infection, presence of hypergastrinemia, or a personal/family history of gastric polyps were excluded from this study. Statistical analyses were performed using SPSS 20 software. Categorical variables were compared by Fisher's exact test; p-values of less than 0.05 were considered statistically significant. Results The prevalence of gastric polyps linked to long-term PPI use was 30%. The minimum duration of daily PPI use required for the formation of polyps is around 24 months. The dosage did not play a significant role in increasing this prevalence. A significant correlation was found between chronic PPI use and factors such as sex, age range, duration, and type of PPI used. These polyps were predominantly found in females (with an OR of 2.9), increased with age, were mostly of the fundic gland type, and their size was proportionally linked to both the dosage and duration of daily PPI use. No cases of dysplasia within the fundic gland polyps (FGPs) were demonstrated in our study. Conclusion To date, there is no current data that prove an association between gastric cancer and PPI-induced FGPs. Additionally, the incidence of FGPs has increased with the widespread chronic use of PPIs. Therefore, attention should be drawn to the potential risk of dysplasia. Thus, the present study highlights the importance of limiting the prescription of PPIs to globally well-defined indications and determining the various risk factors that promote the association between gastric polyps and PPI use. This abstract was recently presented as an E-poster at the ESGE Days 2024 Congress on April 25-27, 2024, in Berlin, Germany.
评估与长期使用质子泵抑制剂（PPI）相关的胃息肉患病率，确定促成这种关联的各种风险因素，并识别与这些息肉相关的特征。方法：这项前瞻性横断面研究在黎巴嫩贝鲁特的两个医院中心，对2021年9月至2022年9月期间前往胃肠病内镜科进行上消化道内镜检查的约1000名患者进行。通过问卷收集服用PPI至少一个月的患者的人口统计学和临床数据。本研究排除所有既往有幽门螺杆菌（H. pylori）感染、存在高胃泌素血症或有胃息肉个人/家族史的患者。使用SPSS 20软件进行统计分析。分类变量采用Fisher精确检验进行比较；p值小于0.05被认为具有统计学意义。结果：与长期使用PPI相关的胃息肉患病率为30%。息肉形成所需的每日PPI使用最短持续时间约为24个月。剂量在增加这种患病率方面未起显著作用。发现长期使用PPI与性别、年龄范围、持续时间和所用PPI类型等因素之间存在显著相关性。这些息肉主要在女性中发现（优势比为2.9），随年龄增加，大多为胃底腺型，其大小与每日PPI使用的剂量和持续时间成比例相关。在我们的研究中，未发现胃底腺息肉（FGP）内有发育异常病例。结论：迄今为止，尚无数据证明胃癌与PPI诱导的FGP之间存在关联。此外，随着PPI的广泛长期使用，FGP的发病率有所增加。因此，应关注发育异常的潜在风险。因此，本研究强调了将PPI处方限制在全球明确界定的适应症范围内以及确定促成胃息肉与PPI使用之间关联的各种风险因素的重要性。本摘要最近于2024年4月25日至27日在德国柏林举行的2024年ESGE Days大会上作为电子海报展示。
